* scPharmaceuticals Inc SCPH.OQ SCPH.O is expected
to show a
rise in quarterly revenue when it reports results on August
10.
* The Burlington Massachusetts-based company is expected to
report revenue of $1.617 million, according to the mean estimate
from 4 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for scPharmaceuticals
Inc is
for a loss of 37 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for
scPharmaceuticals
Inc is $18, above its last closing price of $7.88.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.39 -0.36 -0.30 Beat 17.8
Dec. 31 2023 -0.34 -0.39 -0.30 Beat 22.5
Sep. 30 2022 -0.36 -0.38 -0.37 Beat 3.3
Jun. 30 2022 -0.30 -0.30 -0.35 Missed -15.4
Mar. -0.32 -0.31 -0.28 Beat 9.7
31 2022
Dec. 31 2021 -0.32 -0.34 -0.27 Beat 21.4
Sep. 30 2021 -0.31 -0.31 -0.24 Beat 23.4
Jun. 30 2021 -0.30 -0.30 -0.26 Beat 13.3
This summary was machine generated August 9 at 00:26 GMT. All
figures in US dollars unless otherwise stated